Sign in
TerminatedNo phase

Feasibility of Automated Insulin Delivery With an Interoperable Algorithm Using an Alternative Insulin Pump

Key facts

Who runs it
Imperial College London
Where
United Kingdom1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
1 person enrolled
Started
1 Apr 2022
Ended
31 Aug 2025
Type of study
Interventional
Treatments tested
  • InControl
Record updated
3 September 2025
Why it stopped
Study device not available

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Aged 18 years of age or older
  • Type 1 diabetes confirmed on the basis of clinical features
  • Type 1 diabetes for greater than 1 year
  • On an intensified insulin regimen with multiple dose injection or insulin pump for > 3 months
  • HbA1c >7.5% (58mmol/mol) (or %TIR 3.9-10mmol/L <52% for participants already using a continuous glucose sensor)

Who cannot take part

  • Have active malignancy or under investigation for malignancy
  • Severe visual impairment
  • Total daily insulin dose greater than 100 units
  • Weight greater than 140kg
  • Pregnant or planning pregnancy
  • Reduced manual dexterity
  • Use of any automated insulin delivery system
  • Unable to participate due to other factors, as assessed by the Chief Investigator

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This clinical study assesses the feasibility of implementing the inControl automated insulin delivery algorithm with Dexcom continuous glucose monitoring and a compatible insulin pump in adults with type 1 diabetes. It additionally provides pilot efficacy outcomes for interoperable automated insulin delivery.

The group in the trial

  • Automated Insulin DeliveryTreatment being tested

    The components of the automated insulin delivery system are the Dexcom G6 continuous glucose monitor (CGM), the InControl algorithm and an insulin pump (Ypsomed Ypsopump). The Dexcom G6 continuous glucose monitoring device is an approved device and is licensed to be used to inform insulin dosing decisions without confirmation. The algorithm (inControl 1.0) is approved when used embedded in the Tandem X2 insulin pump. We are using the algorithm for its intended purpose but are implementing it in a smartphone app to be installed in a compatible smartphone (Android). We are additionally assessing incremental benefit with the next software version of the algorithm. This will be the first time this updated software has been assessed in people with type 1 diabetes. The compatible insulin pump is a continuous subcutaneous insulin infusion device and is being used in line with its intended purpose, according to the manufacturer's instructions (YpsoMed Ypsopump).

    Treatment: InControl

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
3 September 2025